The Zhitong Finance App learned that after Neurosecretory Biosciences (NBIX.US) published the results of the DCP Phase III study that fell short of expectations, Deutsche Bank reaffirmed its “hold” rating and maintained a target price of 152 US dollars. The bank believes that investors' expectations for this clinical outcome are low, and the stock price is expected to be minimally affected.

The Zhitong Finance App learned that after Neurosecretory Biosciences (NBIX.US) published the results of the DCP Phase III study that fell short of expectations, Deutsche Bank reaffirmed its “hold” rating and maintained a target price of 152 US dollars. The bank believes that investors' expectations for this clinical outcome are low, and the stock price is expected to be minimally affected.